1. Home
  2. PRG vs DBVT Comparison

PRG vs DBVT Comparison

Compare PRG & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$36.26

Market Cap

1.3B

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$20.28

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
DBVT
Founded
2020
2002
Country
United States
France
Employees
N/A
90
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PRG
DBVT
Price
$36.26
$20.28
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$50.00
$32.04
AVG Volume (30 Days)
387.0K
202.1K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
10.26
EPS
0.89
N/A
Revenue
$2,409,223,000.00
$5,636,000.00
Revenue This Year
$23.77
$35.04
Revenue Next Year
$7.91
$2,360.78
P/E Ratio
$39.92
N/A
Revenue Growth
N/A
35.77
52 Week Low
$25.80
$7.53
52 Week High
$41.14
$26.19

Technical Indicators

Market Signals
Indicator
PRG
DBVT
Relative Strength Index (RSI) 67.66 46.98
Support Level $32.07 $18.88
Resistance Level $36.71 $23.52
Average True Range (ATR) 1.49 0.87
MACD 0.62 -0.01
Stochastic Oscillator 92.84 24.69

Price Performance

Historical Comparison
PRG
DBVT

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: